Therapy | Proposed mechanism | Study subject | Blind | Placebo control | Random assignment | Delivery route | Effect: | Outcomes evaluated |
---|---|---|---|---|---|---|---|---|
Positive | ||||||||
Negative | ||||||||
 | Neutral |  | ||||||
Pharmaceutical approaches | ||||||||
Adenosine [8] | Rats | Not mentioned | Yes | Yes | Intravenous | Positive | Survival, regional blood flow, brain edema, metabolite assay, neurohistopathology, temporalis muscle temperature | |
BDNF [14] | Up regulate Bcl-2, suppress TNF-alpha, increase IL-10, reduce excitotoxicity, promote neural regeneration and axonal sprouting/synaptogenesis [11] | Rats | Not mentioned | Yes | Not mentioned | Intracerebro-ventricular | Neutral | Survival, neurologic function, neurohistopathology |
Anti-apoptosis, modulation of BBB permeability and neuronal excitability [17] | Rats | Not mentioned | Yes | Yes | Intravenous [19] | Positive when combined with TH [19] | Neurologic function [19] | |
HIF-1 alpha activation [18] | Intracerebro-ventricular [21] | Short-term: Positive; Long-term: Neutral [21] | ||||||
Anti-apoptosis, anti-inflammation and enhance neurogenesis [23] | Rats | Not mentioned | Yes | Yes [25] | Subcutaneous [25] | Positive [25] | ||
Not mentioned [26] | Intracerebro-ventricular [26] | Long-term: Negative [26] | p-STAT3, p-AKT1/2/3 and p-ERK1/2 [25] | |||||
Promote neuronal survival and neurogenesis [29] | Mice | Yes | Yes | Positive | ||||
Increase expression of SK2 [32] | Yes [32] | Small-conductance calcium-activated potassium (SK2 and SK3) channel transcripts, electrophysiology [32] | ||||||
Gas-mediator approaches | ||||||||
Increase level of antioxidant glutathione and/or scavenging oxygen species, anti apoptosis and anti-inflammation [37–39] | Yes | Not mentioned | Intravenous | Positive when delivered at or prior to CPR initiation [41–43] | Survival, neurologic function, neurohistopathology [41–44] | |||
Pigs [44] | Yes [43] | Neutral when delivered 10Â min after CPR [41] | Myocardial function, serum nitrite/nitrate levels and hydrogen peroxide level, cardiac mitochondrial swelling [41] | |||||
Enhance NMDA receptors [38] | Negative [44] | Diffusion weighted imaging and MMP-9 activity [42] | ||||||
Cardiac output, heart rate and pulmonary arterial pressure [44] | ||||||||
Attenuation of oxidative and inflammatory injury, inhibition of apoptosis, enhance neurogenesis [47, 48] | Dogs [52] | Not mentioned | Yes | Yes [52] | Inhaled | Positive | ||
Rats [53] | Not mentioned [53] | Oxygen extraction ratio and cerebral oxygen delivery/utilization [52] | ||||||
Expression of Nogo-A/B, Nogo receptors and RhoA expressions [53] | ||||||||
Rats [57] | Not mentioned | Yes | Yes | Inhaled [57] | Positive | |||
Rabbit [58] | Intraperitoneal [58] | Myocardial function, cardiomyocyte degeneration, lung edema and systemic inflammatory response [57] | ||||||
 | Plasma 8-OHDG and MDA level [58] |